This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Romas, E. Articles by Gillespie, M. T. Search for Related Content PubMed PubMed Citation Articles by Romas, E. Articles by Gillespie, M. T.

(American Journal of Pathology. 2002;161:1419-1427.)
© 2002 American Society for Investigative Pathology

Regular Articles

Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis

Evan Romas^*, Natalie A. Sims^*, Daphne K. Hards, Mandy Lindsay, Julian W.M. Quinn, Peter F.J. Ryan, Colin R. Dunstan, T. John Martin and Matthew T. Gillespie

From the University of Melbourne,^* the Department of Medicine, St. Vincent’s Hospital, Fitzroy, Victoria, Australia; St. Vincent’s Institute of Medical Research, Fitzroy, Victoria, Australia; Monash University Medical School, Prahran, Victoria, Australia; and the Department of Pathology, Amgen, Thousand Oaks, California

Rheumatoid arthritis is characterized by progressive synovial inflammation and joint destruction. While matrix metalloproteinases (MMPs) are implicated in the erosion of unmineralized cartilage, bone destruction involves osteoclasts, the specialized cells that resorb calcified bone matrix. RANK ligand (RANKL) expressed by stromal cells and T cells, and its cognate receptor, RANK, were identified as a critical ligand-receptor pair for osteoclast differentiation and survival. A decoy receptor for RANKL, osteoprotegerin, (OPG) impinges on this system and regulates osteoclast numbers and activity. RANKL is also expressed in collagen-induced arthritis (CIA) in which focal collections of osteoclasts are prominent at sites of bone destruction. To determine the role of RANK signaling events in the effector phase of CIA, we investigated effects of Fc-osteoprotegerin fusion protein (Fc-OPG) in CIA. After induction of CIA in Dark Agouti rats, test animals were treated with or without Fc-OPG (3 mg/kg/day) subcutaneously for 5 days, beginning at the onset of disease. Paraffin-embedded joints were then analyzed histologically and the adjacent bone assessed by histomorphometry. Osteoclasts were identified using TRAP staining and expression of the mRNA for OPG and RANKL was identified by in situ hybridization. The results indicated that short-term Fc-OPG effectively prevented joint destruction, even though it had no impact on the inflammatory aspects of CIA. In arthritic joints, Fc-OPG depleted osteoclast numbers by over 75% and diminished bone erosion scores by over 60%. Although cartilage loss was also reduced by Fc-OPG, the effects on cartilage were less striking than those on bone. In arthritic joints OPG mRNA was highly expressed and co-localized with RANK ligand, and treatment with Fc-OPG did not affect the expression of endogenous RANKL or OPG mRNA. These data demonstrate that short term Fc-OPG treatment has powerful anti-erosive effects, principally on bone, even though synovitis is not affected. These findings indicate the potential utility of disrupting RANK signaling to preserve skeletal integrity in inflammatory arthritis.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				M. Stolina, D. Dwyer, M. S. Ominsky, T. Corbin, G. Van, B. Bolon, I. Sarosi, J. McCabe, D. J. Zack, and P. Kostenuik Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses J. Immunol., December 1, 2007; 179(11): 7497 - 7505. [Abstract] [Full Text] [PDF]

				T. J. Martin and K. W. Ng New Agents for the Treatment of Osteoporosis IBMS BoneKEy, November 1, 2007; 4(11): 287 - 298. [Abstract] [Full Text] [PDF]

				T.A. Silva, G.P. Garlet, S.Y. Fukada, J.S. Silva, and F.Q. Cunha Chemokines in Oral Inflammatory Diseases: Apical Periodontitis and Periodontal Disease J. Dent. Res., April 1, 2007; 86(4): 306 - 319. [Abstract] [Full Text] [PDF]

				L. Mancini, M. J. Paul-Clark, G. Rosignoli, R. Hannon, J. E. Martin, I. Macintyre, and M. Perretti Calcitonin and Prednisolone Display Antagonistic Actions on Bone and Have Synergistic Effects in Experimental Arthritis Am. J. Pathol., March 1, 2007; 170(3): 1018 - 1027. [Abstract] [Full Text] [PDF]

				A. R. Pettit, N. C. Walsh, C. Manning, S. R. Goldring, and E. M. Gravallese RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis Rheumatology, September 1, 2006; 45(9): 1068 - 1076. [Abstract] [Full Text] [PDF]

				U.H. Lerner Inflammation-induced Bone Remodeling in Periodontal Disease and the Influence of Post-menopausal Osteoporosis. J. Dent. Res., July 1, 2006; 85(7): 596 - 607. [Abstract] [Full Text] [PDF]

				T. J. Martin Current, New and Emerging Anti-Resorptive Drugs; Antibody Blockade Of RANKL Action IBMS BoneKEy, May 1, 2006; 3(5): 42 - 46. [Full Text] [PDF]

				T. Honda, E. Segi-Nishida, Y. Miyachi, and S. Narumiya Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis J. Exp. Med., February 21, 2006; 203(2): 325 - 335. [Abstract] [Full Text] [PDF]

				M G Ruocco and M Karin IKK{beta} as a target for treatment of inflammation induced bone loss Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv81 - iv85. [Abstract] [Full Text] [PDF]

				F R Byrne, S Morony, K Warmington, Z Geng, H L Brown, S A Flores, M Fiorino, S L Yin, D Hill, V Porkess, et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin Gut, January 1, 2005; 54(1): 78 - 86. [Abstract] [Full Text] [PDF]

				J. E. Onyia, R. J. S. Galvin, Y. L. Ma, D. L. Halladay, R. R. Miles, X. Yang, T. Fuson, R. L. Cain, Q. Q. Zeng, S. Chandrasekhar, et al. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 369 - 379. [Abstract] [Full Text]

				U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text]

				D. O'Gradaigh and J. E. Compston T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion Rheumatology, February 1, 2004; 43(2): 122 - 130. [Full Text] [PDF]

				A. Sakurai, N. Okahashi, I. Nakagawa, S. Kawabata, A. Amano, T. Ooshima, and S. Hamada Streptococcus pyogenes Infection Induces Septic Arthritis with Increased Production of the Receptor Activator of the NF-{kappa}B Ligand Infect. Immun., October 1, 2003; 71(10): 6019 - 6026. [Abstract] [Full Text] [PDF]

				M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]